A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.

Studied

Randomized double-blind trial of daily liraglutide 3.0 mg versus placebo, both with lifestyle therapy, for 56 weeks followed by 26 weeks off treatment.

Who / model

Adolescents aged 12 to under 18 with obesity and poor response to lifestyle therapy, with 125 assigned liraglutide and 126 assigned placebo.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

At week 56, the estimated difference in BMI standard-deviation score was -0.22 in favor of liraglutide. At least 5% BMI reduction occurred in 43.3% versus 18.7%. Gastrointestinal events occurred in 64.8% versus 36.5%, and discontinuations in 10.4% versus 0. BMI score increased more after liraglutide was stopped.

Limits

The study involved adolescents who had not responded adequately to lifestyle therapy, so results do not establish outcomes in other populations. Follow-up after treatment lasted 26 weeks. Novo Nordisk funded the trial.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary